A detailed history of First Horizon Advisors, Inc. transactions in Organon & Co. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 39 shares of OGN stock, worth $628. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39
Previous 170 77.06%
Holding current value
$628
Previous $3,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$17.45 - $21.96 $2,285 - $2,876
-131 Reduced 77.06%
39 $0
Q1 2024

Apr 26, 2024

SELL
$13.78 - $18.8 $2,756 - $3,760
-200 Reduced 54.05%
170 $3,000
Q4 2023

Feb 06, 2024

SELL
$10.95 - $17.32 $6,559 - $10,374
-599 Reduced 61.82%
370 $5,000
Q3 2023

Oct 27, 2023

BUY
$16.59 - $23.77 $13,006 - $18,635
784 Added 423.78%
969 $16,000
Q2 2023

Aug 03, 2023

SELL
$19.27 - $24.63 $5,858 - $7,487
-304 Reduced 62.17%
185 $3,000
Q1 2023

May 15, 2023

SELL
$21.42 - $32.08 $1,863 - $2,790
-87 Reduced 15.1%
489 $11,000
Q4 2022

Feb 10, 2023

BUY
$23.31 - $28.61 $2,121 - $2,603
91 Added 18.76%
576 $16,000
Q3 2022

Nov 09, 2022

SELL
$23.4 - $34.25 $2,199 - $3,219
-94 Reduced 16.23%
485 $11,000
Q2 2022

Aug 02, 2022

SELL
$31.66 - $38.9 $7,376 - $9,063
-233 Reduced 28.69%
579 $19,000
Q1 2022

May 10, 2022

SELL
$30.45 - $39.36 $44,883 - $58,016
-1,474 Reduced 64.48%
812 $28,000
Q4 2021

Feb 09, 2022

SELL
$28.67 - $37.13 $31,020 - $40,174
-1,082 Reduced 32.13%
2,286 $69,000
Q3 2021

Nov 15, 2021

SELL
$28.63 - $35.64 $24,450 - $30,436
-854 Reduced 20.23%
3,368 $110,000
Q3 2021

Nov 09, 2021

BUY
$28.63 - $35.64 $36,274 - $45,155
1,267 Added 42.88%
4,222 $138,000
Q2 2021

Aug 09, 2021

BUY
$28.45 - $38.0 $84,069 - $112,290
2,955 New
2,955 $89,000

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $4.1B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.